apoptosis rate in vitro compared to good prognosis CLL cells. This in vitro finding was consistent with the in vivo demonstration of higher LDH levels in patients with poor prognosis CLL. 3 Together, our results and those of Longo suggest that poor prognosis CLL is accompanied by a higher CLL cell turnover (that is, both proliferation and apoptosis). Given this finding, it is important to recognize that equating a tendency of poor prognosis CLL to proliferate in response to CpG ODN with a lack of potential clinical efficacy does not take sensitivity to apoptotic signals into account. It is the balance of proliferation and apoptosis that is most important.
We also evaluated how cytogenetics impacts on immunologic phenotype of the CLL cells. Poor prognosis CLL cells had significantly lower levels of immunologically relevant surface proteins (costimulatory, antigen-presenting and cell adhesion molecules) compared to CLL cells from the good prognosis group. 3 Functionally, CLL cells from the poor prognosis group induced less T-cell proliferation in mixed lymphocyte cultures than CLL cells from the good prognosis group. We previously published that CLL cells respond to CpG ODN by increasing the expression of these molecules. 4 Recently we have found that CpG ODN increases the expression of immunostimulatory molecules in all CLL samples irrespective of their cytogenetic status (Figure 1a) , and that allogeneic T-cell responses were stronger towards CLL cells pretreated with CpG ODN compared to untreated CLL cells irrespective of cytogenetics (Figure 1b) .
Taken together, these studies suggest that measurement of proliferation is only one aspect of the effect CpG ODN has on CLL cells. Induction of apoptosis and enhancement of an immunostimulatory phenotype may also be important. Our studies and those of Longo are consistent in that they demonstrate that CLL with poor prognosis genes, as measured by both cytogenetics and mutational status, are more likely to proliferate in response to CpG ODN than CLL with good prognosis genes. However, our studies, exploring the rate of turnover of CLL cells, and the effect of CpG ODN on the phenotype of the CLL cells, suggest CpG ODN could, indeed, have beneficial effects on CLL irrespective of genetic prognostic factors.
We are currently conducting a phase I trial of CpG ODN in CLL. This study is open to CLL subjects irrespective of cytogenetics or mutational status, and includes extensive laboratory correlation exploring phenotypic changes and evaluation of the tendency of the CLL cells to undergo apoptosis before and after therapy. While this phase I trial is not powered to compare poor to good prognosis CLL, it is an important first step in determining whether CpG ODN is likely to be of use in subjects with CLL, and if so, which patients are most likely to be benefited. In our recent article, we addressed the issue of the different proliferative capacity of CLL B-cells from patients with progressive disease and poor prognostic features (V H unmutated) and patients with stable disease and good prognostic features (V H mutated). 1 During this study, we also observed that CpG ODN stimulation leads to cell cycle arrest and induction of apoptosis in CLL B cells from most cases with stable disease and mutated V H genes. In contrast, CpG ODN stimulation either had no effect on leukemic cell survival or resulted in decreased spontaneous apoptosis in the majority of cases with progressive disease and unmutated V H genes. These data were obtained by annexin V/propidium iodide analysis of CLL B-cells cultured for 48 h with or without CpG ODN. The results were presented in our paper and are shown again in Figure 1a . Thus, our conclusion that CpG ODN may not be an effective treatment in a subset of poor prognosis patients was based on direct assessment of apoptotic sensitivity, and was not based on the 'tendency of poor prognosis CLL to proliferate in response to CpG ODN', as suggested by Jahrsdorfer et al.
2 in their letter. Sensitivity to CpG ODN-induced apoptosis was additionally investigated in selected cases by analysis of PARP cleavage. These data are now presented in Figure 1b and confirm that certain CLL cases, mainly those with progressive disease and unmutated V H genes, are resistant to CpG ODN-induced apoptosis. Together, these observations lead us to suggest that CpG ODN may not be effective in a subset of poor prognosis patients, unless pathways that regulate pro-survival signaling are not blocked simultaneously. However, we agree with Jahrsdorfer et al. Acute promyelocytic leukemia (APL), which accounts for about 10% of acute myeloid leukemias, is characterized by the presence of the specific chromosomal translocation t(15;17)(q22;q21). This translocation produces the fusion of the retinoic acid receptor a (RARA) gene on chromosome 17 with the promyelocytic leukemia (PML) gene. 1 The breakpoints in the RARA gene are located within 15 kb of intron 2. Three regions of the PML locus are involved in the translocation breakpoints: bcr1 in intron 6, bcr3 in intron 3 and bcr2 in exon 6. Patients with short bcr2 transcripts as a consequence of exon 6 PML deletions are referred as V-form PML-RARa. [2] [3] [4] In this work, we report an unusually large exon 6 PML deletion (161 bp) associated with a short intron capture (5 bp), giving rise to a net 156 bp deletion (52 amino acids). The outcome was good.
A 33-year-old Honduran woman who had been living in Catalonia for 2 years was admitted to the Hospital Josep Trueta at Girona in September 2006 with marked asthenia and easy bruising on both legs. Blood analysis showed hemoglobin of 64 g/l, mean corpuscular volume (VCM) 82.9 fl, hematocrit 18%, leukocytes 2.6 Â 10 9 /l (neutrophils: 11%; lymphocytes: 36%; monocytes: 9%; blasts: 43% with coarse granules and Auer rods) and platelets, 60 Â 10 9 /l. The international normalized ratio of prothrombin (INR) time was 1.84 and fibrinogen 126 mg/dl. A bone marrow aspirate performed at admission disclosed a typical picture of acute promyelocytic leukemia and the karyotype was 46, XX, t(15;17)(q22;q21.1).
Molecular findings revealed a short type bcr 2 transcript (V-form) with a net 156 bp deletion (Figure 1 Increased amounts of cleaved PARP indicate activation of the caspase cascade and can be seen in cases G56, G77, G101 and G57. In the remaining cases, the levels of cleaved PARP do not change or decrease, indicating protection from spontaneous apoptosis. Additional clinical and laboratory features for the patients investigated in this series can be found in Longo et al.
